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Abstract 
MicroRNAs (miRNA) are small endogenously expressed non-coding RNAs that negatively 
regulate expression of protein-coding genes at the translational level. Accumulating evidence, 
such as aberrant expression of miRNAs, suggests that they play a role in the development of 
cancer. They have been identified in various tumor types, demonstrating that different sets of 
miRNAs are usually deregulated in different cancers. To identify the miRNA signatures spe-
cific for Hepatitis C virus (HCV)-associated Hepatocellular carcinoma (HCC), miRNA ex-
pression profiling of 32 HCC post-HCV infected, 74 HCV-positive and 12 control individuals 
was carried out using whole genome expression profiling. Differential expression of two in-
dividual miRNAs between control and high risk HCV patients was detected and found to 
possibly target genes related to HCC development and progression. The sensitivity and 
specificity of miR-618 for detecting HCC among HCV-positive individuals was found to be 
64% and 68%, respectively. Whereas, the sensitivity and specificity of miR-650 were 72% and 
58%, respectively. Additionally, the sensitivity and specificity for miR-618/650 in tandem were 
58% and 75%, respectively. These predictive values are greatly improved compared to the 
traditional α-feto protein (AFP) level-based detection method. The proposed HCC miRNA 
signatures may therefore be of great value for the early diagnosis of HCC, before the onset of 
disease in HCV-positive patients. The significance of this approach is amplified by the use of 
urine as a  sample  source as  it offers a  non-invasive approach  for developing screening 
methods that can reduce mortality rates. 
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Introduction 
Hepatocellular  carcinoma  (HCC)  is  one  of  the 
leading causes of deaths worldwide and is responsi-
ble for 500,000 deaths per year (1). Individuals chron-
ically infected with hepatitis B or C virus (HBV, HCV) 
are  at  high  risk  for  the  development  of  HCC,  with 
disease progression occurring persistently over many 
years  (2).  Hepatitis  B  virus  (HBV)  and  Hepatitis  C 
virus (HCV) are the major risk factors for the devel-
opment of HCC. Worldwide, approximately 370 mil-
lion  individuals  are  HBV  positive  and  130  million 
HCV positive (3). The development  of HCC is also 
associated  with  other  risk  factors  including  gender, 
age and dietary factors (such as Aflatoxin B1 and al-
cohol) (4).  
The major potentially curative form of therapy is 
still surgical resection, however only 10% of patients 
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were at operable stages upon disease discovery. This 
is mainly due to the absence of reliable tools for early 
diagnosis and thus most patients were at a late stage 
either for surgical solutions or for effective treatment 
(5).  The  widely  used  serological  tumor  markers  for 
HCC,  α-fetoprotein  (AFP)  and  des-γ-carboxy  pro-
thrombin (DCP), lack specificity and sensitivity. AFP 
specificity and sensitivity are 75% and 68%, respec-
tively, whereas elevated DCP activity is only present 
in 44-47% of HCCs less than 3 cm in size (6, 7, 8). Most 
chronically infected patients remain asymptomatic for 
many  years  and  the  long  latency  between  infection 
and  development  of  HCC  provides  an  important 
window  of  time  during  which  individuals  can  be 
monitored  for  disease  progression  and  intervention 
could be efficient (9). Therefore, the development of 
non-invasive  biomarkers  with  high  sensitivity  and 
specificity that can be used for large-scale clinical in-
vestigations would be highly beneficial. 
Various  molecular  alterations,  leading  to 
dysregulation of well-known molecular pathways in 
carcinogenesis,  take  place  in  the  cancerous  nodules 
and appear in HCCs (10, 11). Some of these pathways 
have recently been discovered as being regulated by 
microRNAs (miRNAs). MiRNAs are short noncoding 
RNAs (~22 nucleotides) that are believed to play an 
important  role  in  the  regulation  of  gene  expression 
and  hence  control  many  biological  processes  (12). 
Since the discovery of miRNAs in 1993 in the nema-
tode  Caenorhabditis  elegans  (13),  470  miRNAs  have 
been described in the miRBase database v9.15 and 265 
potential  miRNAs  have  also  been  identified  in  a 
RAKE analysis study (14, 15). 
The production of a mature miRNA occurs in a 
stepwise  manner,  starting  with  a  large  RNA  Pol  II 
transcript that is processed by the sequential action of 
several proteins/enzymes of the RNAi pathway, re-
sulting in the generation of a short double stranded 
RNA  molecule  (16).  The  “effector”  (or  antisense) 
strand of this short dsRNA molecule is incorporated 
into and guides the RNA-induced silencing complex 
(RISC)  to  its  target  mRNA  (17).  Recognition  of  the 
target  is  facilitated  by  partial  (or  in  rare  cases  full) 
sequence complementarity between the miRNA and 
its target mRNA. Binding of the RISC to mRNA may 
result  in  translational  repression  if  base  pairing  be-
tween the miRNA and its target mRNA is imperfect 
(as is the case for most of the miRNA mediated si-
lencing), or mRNA target degradation, in case of full 
complementarity. MiRNA expression profiles seem to 
be tissue-specific and tumor-specific (18).  
Half of the known miRNAs are localized inside 
or close to fragile sites, in minimal sites of loss of het-
erozygosity  and  at  familiar  breakpoints  associated 
with cancer (19). Several recent studies have verified 
that miRNA expression signatures may have a signif-
icant  impact  on  the  classification,  diagnosis  and 
prognosis of the disease in cancer patients (20, 21). A 
comprehensive analysis of the miRNA expression in 
different  cancers  showed  a  higher  diagnostic  and 
prognostic  accuracy  for  the  miRNA  genetic  finger-
print than for more than 16,000 mRNAs (21). Recently, 
the biological functions and targets of some miRNAs 
have been reported. MiR-375 regulates insulin secre-
tion by modulating the expression of myotropin (22). 
Abnormal expression of the miR-155 precursors, ma-
ture miR-15 and miR-16 were described in malignant 
lymphomas  (19,  23).  Furthermore,  the  downregula-
tion  of  miR-143  and  miR-145  was  reported  in  colo-
rectal  neoplasia  (16).  In  addition,  miR-372  and 
miR-373  neutralize  p53-mediated  cyclin-dependent 
kinase  inhibition and  hence allow tumor  growth in 
the presence of wild-type p53 (24). 
Understanding  the  pathogenesis  of  vi-
ral-associated HCC is important in developing effec-
tive means of prevention and treatment of this highly 
malignant form of cancer (25). Nowadays, the identi-
fication  of  a  non-invasive  biological  biomarker  that 
can be used to screen high-risk patients in order to 
enhance HCC detection, earlier intervention and in-
crease  the  probability  of  successful  treatment  is  ur-
gently needed. In the present study, the miRNA ex-
pression profiles in urine samples collected from HCC 
post  HCV-postitive  group,  HCV-postitive  group  as 
well  as  from  healthy  control  group  were  analyzed. 
MiRNA profiling was firstly carried out on miRNA 
isolated from urine samples pooled from each group 
using  the  miRNA  expression  profiling  assay  panel 
(Illumina). Furthermore, we evaluated the deregula-
tion of 5 miRNAs, revealed from our data, as putative 
non-invasive  urinary  biomarkers  for  screening 
high-risk patients for the early detection of HCC. 
Materials and Methods 
Urine  sample  collection.  Urine  samples  were 
collected  from  the  general  hospital  at  Alexandria 
University (Alexandria, Egypt) and the National In-
stitute  for  Liver  Diseases  at  Menoufia  University 
(Shebeen El-Kome, Egypt) upon the approval of the 
Research Ethics Board at Brock University (St. Cath-
arines, Canada). Urine samples were collected (50mL) 
in the presence of 5 mM EDTA (final concentration). 
All the samples were divided into 3 groups based on a 
questionnaire  filled  by  the  clinician  responsible  for 
each patient. The 3 groups participating in this study 
were  divided  as  follows:  32  patients  with  HCC 
post-HCV  infection,  74  patients  with  chronic  HCV 
infection and 12 normal individuals (Table 1). Patients  Journal of Cancer 2012, 3 
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with other conditions such as HBV/HCV co-infection 
and Schistosomiasis were excluded. All three groups 
were examined by HCV 5’ non-coding region reverse 
transcriptase PCR (5’ NCR RT-PCR). The results con-
firmed  that  the  HCC  post-HCV  and  HCV-positive 
patients share the same etiological factor, HCV geno-
type 4 (data not shown). 
 
 
Table 1. Clinical pathological parameters of the patients 
involved in this study. 
  Control group  HCC post-HCV 
group 
HCV-positive 
group 
Number of pa-
tients 
12  32  74 
Age (mean ± SD)  28 ±4  50 ±8  36 ±18 
HCV RNA*  -Ve  +Ve  +Ve 
Sex  Male (6) 
Female (6) 
Male (26) 
Female (6) 
Male (50) 
Female (24) 
* All patients were confirmed to be HCV positive or negative by 
polymerase chain reaction for HCV NCR. Sequencing the PCR 
product confirmed the genotype of the HCV to be genotype 4.  
 
 
 
 
Isolation of total RNA from urine. Total RNA 
was isolated from 3mL of urine using the Urine (Ex-
foliated  cell)  RNA  Purification  Kit  (Norgen  Biotek, 
Thorold, ON, Canada). The isolation was performed 
using a modified protocol. Briefly, 3mL of urine was 
mixed with 350μL of lysis solution. The sample was 
vortexed  for  15  seconds  and  the  lysate  was  then 
transferred to an RNase-free microcentrifuge tube. To 
the lysate, 200μL of 95-100% ethanol was added and 
mixed by vortexing for 10 seconds. The lysate + eth-
anol  were  applied  to  the  column.  The  column  was 
then centrifuged for 1min at 10,000 rpm. After cen-
trifugation, the flow-through was discarded and the 
spin  column  was  re-assembled  with  the  collection 
tube. The previous step was repeated until all the ly-
sate had been loaded onto the column. The column 
was washed twice by applying 500μL wash solution 
to  the  column  and  centrifuging  for  1min  at  10,000 
rpm. The column was spun for an additional minute 
at  14,000  rpm  to  ensure  that  the  column  was  com-
pletely  dry  prior  to  RNA  elution.  The  column  was 
placed into a new 1.7mL elution tube (provided with 
the kit). To the column, 50μL of elution buffer was 
added and the column was spun down for 2min at 
2,000 rpm followed by a 1min spin at 14,000rpm. The 
purified RNA sample was stored at –70°C till further 
analysis.  
Capillary electrophoresis. The purified miRNAs 
were loaded onto an Agilent® RNA Nano 6000 chip 
and  resolved  on  an  Agilent®  2100  BioAnalyzer  ac-
cording  to  the  manufacturer’s  instruction  (Agilent 
Technologies).  
MicroRNA  whole-genome  expression  profil-
ing. The differential miRNA expression profiling was 
performed  using  the  miRNA  expression  profiling 
assay  panel  (Illumina,  San  Diego,  CA,  USA)  at  the 
SickKids genomic core facility (Toronto, ON, Canada). 
This  assay  is  an  adaptation  of  the  proven  DASL® 
(cDNA-mediated Annealing, Selection, Extension and 
Ligation)  assay.  Hybridization  and  scanning  of 
miRNA  expression  bead  array  was  performed  ac-
cording to the manufacturer’s instructions (Illumina, 
San Diego, CA, USA).  
Relative  expression  profiling  for  candidate 
miRNAs  using  RT-qPCR.  Relative  miRNA  expres-
sion  levels  for  the  5  candidate  miRNAs  (miR-625, 
miR-532, miR-618, miR-516 and miR-650) were ana-
lyzed  among  the  HCC  post  HCV-positive  group, 
HCV-positive  group  and  the  control  group.  Candi-
date miRNAs were reversibly-transcribed using 3µl of 
RNA template and 0.5µl gene-specific stem-loop RT 
primer (Table 2). The reaction was then made up with 
RNase-free water to 5μL and incubated for 5 mins at 
70°C  followed  by  a  10  minute  incubation  at  4°C. 
During  the  4°C  incubation,  a  mix  of  10µl  5X  first 
strand  Buffer,  5µl  of  0.1mM  DTT,  2.5µl  of  10mM 
dNTPs,  2µl  SuperScript  III  (Invitrogen)  and  25.5µl 
nuclease-free water were added to the initial reaction 
for a final reaction volume of 50µL. The final reaction 
was then incubated at 25°C for 10 min, 42°C for 90 
min,  70°C  for  15  min  with  a  final  hold  at  4°C.  For 
controls, minus RT reactions were set up (only for the 
control group) where the enzyme was replaced with 
nuclease-free water. All samples were analyzed using 
the iCycler iQ real time PCR detection system with iQ 
SYBR  Green  Supermix  (BioRad  Laboratories).  For 
each sample, 3μl from its corresponding RT reaction 
were  mixed  in  a  7.5μl  iQ  SYBR  Green  Supermix, 
4.26μl  nuclease-free  water  and  0.12μl  each  specific 
forward  and  reverse  miRNA  primer  (Table  2)  in  a 
total of 15μl. All RT-qPCR experiments were carried 
out in triplicate and the expression levels were nor-
malized  to  5S  rRNA  levels.  The  relative  expression 
level (fold change) for each candidate miRNA within 
each  group  was  then  calculated  using  the  equation 
2-∆Ct test / 2-∆Ct control. 
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Table 2. List of oligonucleotides used in this project. 
Name  Sequence 
SL-miR-625  5’GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATA CGACAGGACT 3’ 
miR-625 (Forward)  5’ AGGGGGAAAGTTCTATAG-3’ 
SL-miR-532  5’GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATA CGACACGGTC 3’ 
miR-532 (Forward)  5’ CATGCCTTGAGTGTAGGA 3’ 
SL-miR-618  5’GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATA CGACACTCAG 3’ 
miR-618 (Forward)  5’ AAACTCTACTTGTCCTTCTG 3’ 
SL-miR-516  5’GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGA CAAAGTG 3’ 
miR-516 (Forward)  5’ CATCTGGAGGTAAGAAGCAC 3’ 
SL-miR-650  5’GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATAC GACGTCCTG 3’ 
miR-650 (Forward)   5’ AGGAGGCAGCGCTCTCAG 3’ 
5S rRNA (Forward)  5’ GCCATACCACCCTGAACG 3’ 
5S rRNA (Reverse)  5’ AGCCTACAGCACCCGGTATT 3’ 
 
 
Results 
Micro-RNA Microarray Expression Profiles 
among HCC-post HCV positive, HCV positive 
and control group 
Micro-RNA was isolated using the miRNA puri-
fication  Kit  (Norgen  Biotek,  Thorold,  ON,  Canada) 
from  urine  samples  pooled  from  the  three  groups 
participating  in  this  project  (i.e.  HCC  post 
HCV-positive group, HCV-positive group and control 
group). The quality and the quantity of the isolated 
miRNA were tested using the Agilent RNA 6000 Kit. 
The  RNA  concentrations  in  the  HCC  post 
HCV-positive  group,  HCV-positive  group  and  the 
control  group  were  82ng/μL,  148ng/μL  and 
30ng/μL, respectively.  
Differential expression analyses of miRNA iso-
lated from pooled urine samples was performed using 
the illumina MicroRNA Expression Profiling Assay, 
which includes 470 miRNAs described in the miRBase 
database v9.15 and 265 potential miRNAs identified 
in a RAKE analysis study (14, 15). The signal intensity 
of  each  gene  in  the  HCC-post  HCV  positive  group 
and the HCV positive group was normalized against 
its equivalent in the control group (Figure 1). After 
calculating the fold change in the expression of dif-
ferent miRNAs in the HCC-post HCV positive group 
and in the HCV positive group relative to the control 
group, miR-152, miR-486, miR-219, miR452*, miR-425, 
miR-154 and miR-31 were significantly up-regulated 
only  among  chronic  HCV  patients.  Furthermore, 
miR-640, miR-765, miR-200a, miR-521 and miR-520* 
were significantly up-regulated only in the HCC-post 
HCV positive group, relative to their expression (or 
lack  thereof)  in  the  control  group.  MiR-453  and 
miR-610 were expressed relatively weakly in the con-
trol  group,  but  their  expression  was  markedly  in-
creased  in  the  HCC-post  HCV  positive  group.  It 
should  also  be  noted  that  miR-486  and  miR-219 
(up-regulated among the HCV-positive group) were 
found  to  be  down-regulated  in  the  HCC-post  HCV 
positive group.  
The opposite was true for the expression levels 
of miR-765, miR200a and miR-610, which were sig-
nificantly up-regulated in the HCC-post HCV group 
but were down-regulated in the HCV positive group. 
Moreover,  miR-323,  miR-449,  miR-502d,  miR-92b, 
miR-516-5p and miR-650 were found to be commonly 
down-regulated in both the HCC-post HCV positive 
group and in the HCV positive group, relative to the 
control  group.  Finally,  miR-335,  miR-618,  miR-625, 
miR-532,  miR-7  were  found  to  be  commonly 
up-regulated  in  both  the  HCC-post  HCV  positive 
group and in the HCV positive group, relative to the 
control group. Scanning the TargetScan and MiRanda 
databases  (26)  revealed  that  the  commonly 
up-regulated  miRNAs  (miR-625,  miR-532  and 
miR-618) were likely playing a significant role in the 
development of HCC among high risk HCV positive 
patients. The methyl-CpG binding domain protein 2 
gene  (MBD2)  is  likely  to  be  targeted  by  miR-625. 
MiR-532  likely  targets  ligase  I,  DNA,  and  the 
ATP-dependent gene (LIG 1), whereas, the putative 
target  of  miR-618  was  found  to  be  the  low  density 
lipoprotein-related protein 12 (LRP12).     Journal of Cancer 2012, 3 
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Figure  1 Heat map of miRNA expression in HCC-post HCV positive, HCV positive and control group. A) MiRNA 
up-regulated in HCC-post HCV positive and HCV positive group. B) MiRNA de-regulated in both HCC post HCV-positive 
and HCV-postitive group relative to the control group. The signal intensity from each miRNA tested in either the HCC or 
the HCV groups was normalized against its equivalent in the control group. 
 
Validation of miR-625, miR-532, miR-618, 
miR-516-5p and miR-650 Deregulation among 
HCC-post HCV positive Patients using 
RT-qPCR 
Five  of  the  miRNAs,  three  up-regulated 
(miR-625,  miR-532  and  miR-618)  and  two 
down-regulated  (miR-516-5P  and  miR-650),  whose 
levels were significantly different in the urine pooled 
from the HCC post HCV-positive group relative to the 
control  group,  were  studied  as  potential  HCC  bi-
omarker(s) since their putative targets have a role in 
cancer development. In order to evaluate their poten-
tial  as  biomarkers,  the  relative  expression  levels  of 
these miRNAs were examined among patients in the 
HCC-post HCV positive group, using RT-qPCR. Each 
gene was normalized against the 5S rRNA for both the 
HCC post HCV-positive and the control group. The 
relative expression of each miRNA was calculated as a 
fold difference of expression, using the equation 2-∆Ct 
(target miRNA) HCV / 2-∆Ct (target miRNA) control. 
Differences  in  the  expression  levels  of  miRNAs  be-
tween the groups were considered significant when 
there was a three or more fold difference in expression 
and the p value was less than 0.05 (Figure 2).  
MiR-625, miR532 and miR-618 were found to be 
significantly up-regulated in 56%, 62.5% and 72% of 
HCC-post HCV positive patients, respectively (i.e. 18, 
20 and 23 of 32 patients). Moreover, miR-516-5p and 
miR-650  were  found  to  be  significantly 
down-regulated  in  50%  and  72%  of  HCC  post 
HCV-positive patients, respectively (i.e. 16 and 23 of 
32 patients).   Journal of Cancer 2012, 3 
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Figure 2. A Volcano Plot graphs the log2 for the fold difference in A) miR-625, B) miR-532, C) miR-618 D) miR-516-5p and 
E) miR-650 expression versus its p value from the t-test among HCC-post HCV positive group. The black line indicates a 
fold-change in gene expression of 1. The pink lines indicate the desired fold change in miRNA expression threshold (2). The 
blue line indicates the desired threshold for the p value of the t-test (P < 0.05). Samples with a significant miRNA deregu-
lation (dotted oval) were chosen at a fold difference ≥ 3 and p < 0.05. 
 
Screening the Expression of miR-618 and 
miR-650 among High-Risk HCV positive pa-
tients using qRT-PCR 
Since the deregulation of expression of miR-618 
and  miR-650  appeared  to  be  a  characteristic  event 
among  HCC  patients,  with  72%  of  HCC-post  HCV 
positive patients exhibiting this deregulated pattern 
of expression, the expression levels  of miR-618 and 
miR-650 were examined among the 74 HCV positive 
patients using RT-qPCR in order to evaluate the po-
tential  of  using  these  aberrant  miRNA  expression 
signatures as an HCC biomarker. MiR-618 was sig-
nificantly (three or more fold difference in expression 
levels and a p value of the student t-test lower than 
0.05) up-regulated in 35 of the 74 HCV positive pa-
tients  (Figure  3A),  while,  miR-650  was  significantly 
down-regulated in 42 of the 74 HCV positive patients 
(Figure 3B).   Journal of Cancer 2012, 3 
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Figure 3 A Volcano Plot graphs the log
2 for the fold difference in A) miR-618 and B) miR-650 expression versus its p value 
from the t-test among HCV positive group. The black line indicates a fold-change in gene expression of 1. The pink lines 
indicate the desired fold-change in gene expression threshold (3). The blue line indicates the desired threshold for the p 
value of the t-test (P < 0.05). Samples with a significant miRNA deregulation (dotted oval) were chosen at a fold change ≥ 3 
and p < 0.05. 
 
 
Diagnostic Value of miR-618 and miR-650 for 
the Detection of HCC among High-Risk HCV 
infected Patients 
To evaluate the potential of using aberrant ex-
pression of miR-618 and miR-650 for diagnostic pur-
poses, the medical records, specifically AFP levels and 
CT  scan  results,  of  all  HCV-positive  patients  were 
updated  two  years  after  initial  sample  collection.  It 
should be noted that all HCV positive patients were 
diagnosed as being HCC-free (AFP level lower than 
400ng/L and a negative CT scan) at the time of initial 
sample collection. The specificity, sensitivity and the 
diagnostic  accuracy  of  miR-618  up-regulation  and 
miR-650 down regulation  (separately or in tandem) 
for diagnosing HCC were then determined, based on 
the  updated  medical  records  of  HCV  patients.  The 
following  criteria  were  applied:  patients  with  AFP 
levels of 400ng/L or more, with a positive CT scan, 
and  exhibiting  significant  deregulation  of  either 
miR-618  or  miR-650  expression,  or  deregulation  of 
both, were considered true positives; patients whose 
AFP levels were 400ng/L or more, with a positive CT 
scan,  and  not  exhibiting  significant  deregulation  of 
any of the miRNAs (either separately or in tandem) 
were  considered  false  negatives;  patients  with  AFP 
levels lower than 400ng/L, with a negative CT scan, 
and exhibiting significant deregulation of miR-618 or 
miR-650  expression,  or  deregulation  of  both,  were 
considered false positives; and finally, samples with 
AFP  levels  lower  than  400ng/L  and  not  exhibiting 
significant deregulation of either miR-618 or miR-650 
expression, or deregulation of both, were considered 
true negatives.  
By  applying  the  above  mentioned  criteria  (see 
also  Table  3),  the  sensitivity  and  the  specificity  of 
miR-618  up-regulation  for  detecting  HCC  among 
HCV-positive patients, based on AFP levels and CT 
scan results, were 64% and 68%, respectively with a 
66% diagnostic accuracy. Whereas, the sensitivity and 
the  specificity  of  miR-650  down-regulation  for  de-
tecting HCC among HCV-positive patients were 72% 
and 58%, respectively with a 65% diagnostic accuracy. 
Additionally,  the  sensitivity  and  the  specificity  of 
tandem deregulation of miR-618 and miR-650 expres-
sions for detecting HCC were 58% and 75%, respec-
tively with a diagnostic accuracy of 69%. There was 
no  correlation  between  the  relative  expression  of 
miR-618 or miR-650 and AFP levels. 
 
Discussion 
MicroRNAs (MiRNAs) are negative gene regu-
lators that have been shown to control many crucial  Journal of Cancer 2012, 3 
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biological  processes,  such  as  cellular  proliferation, 
cellular  differentiation  and  apoptosis.  Not  surpris-
ingly, miRNAs play a critical role in the initiation and 
progression  of  human  cancer  (27).  Recent  evidence 
indicates  that  miRNAs  can  act  as  both  tumor  sup-
pressors and oncogenes (or oncomirs) (28). Half of the 
known miRNAs are localized inside or close to fragile 
sites,  sites  of  loss  of  heterozygosity  and  at  familiar 
breakpoints associated with cancer (19). Several recent 
studies  reported  that  miRNA  expression  signatures 
may  have  a  significant  impact  on  the  classification, 
diagnosis  and  prognosis  of  cancer  (20,  21).  A  com-
prehensive analysis of miRNA expression in different 
cancers  showed  a  higher  diagnostic  and  prognostic 
accuracy than expression profiling of 16,000 mRNAs 
(21).  
 
Table 3. A list showing the fold change, p values for the expression of miR-618, miR-650 as well as the AFP levels for each 
patient in the Testing set. 
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Understanding  the  pathogenesis  of  vi-
ral-associated HCC is important for developing effec-
tive means of prevention and treatment of this highly 
malignant form of cancer (25). Currently, the identi-
fication  of  a  non-invasive  biological  biomarker  that 
can be used to screen high-risk patients is urgently 
needed to enhance HCC detection, resulting in earlier 
intervention  and  increasing  the  probability  of  suc-
cessful treatment. Recent studies have already identi-
fied several miRNAs whose expression is deregulated 
in viral hepatitis infections and in HCC (29). Although 
important information was gathered about the hepa-
tocarcinogenic  effect  of  these  deregulated  miRNAs 
and the viral-host interactions that lead to the viral 
pathogenic effect, none of these studies evaluated the 
potential  of  using  deregulated  miRNA  expression 
patterns to predict the development and progression 
of HCC among high-risk HCV infected patients. 
The  aim  of  our  biomarker  discovery  approach 
was to investigate the potential of using deregulation 
of miRNA expression in HCC-post HCV infected pa-
tients  for  the  early  diagnosis  of  HCC  in  high  risk 
groups.  The  expression  levels  of  miRNAs  isolated 
from  urine  were  studied  using  the  Illumina  Mi-
croRNA Expression Profiling Assay. To analyze the 
global differences in miRNA expression patterns be- Journal of Cancer 2012, 3 
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tween the two test groups participating in this study 
and the control group, the miRNAs isolated from in-
dividuals belonging to the same group were pooled 
together and analyzed. After analysis, four different 
categories  of  differentially  expressed  miRNAs  were 
identified.  The  first  category  of  miRNAs  were 
up-regulated only in the HCV positive group, relative 
to  the  control  group  (miR-152,  miR-486,  miR-219, 
miR452*, miR-425, miR-154 and miR-31). The second 
category  of miRNAs were up-regulated only in the 
HCC-post HCV positive group, relative to the control 
group  (miR-640,  miR-765,  miR-200a,  miR-521  and 
miR-520a*). The miRNAs identified in these two cat-
egories are important for studying HCV pathogenic-
ity, HCV-host interaction, and the hepatocarcinogenic 
effect of miRNA as a consequence of HCV infection. 
Unfortunately, these miRNAs can not be used as HCC 
biomarkers because they were not commonly dereg-
ulated in the HCC-post HCV positive group and the 
HCV positive group.  
The expression of ten miRNAs was commonly 
deregulated  in  both  the  HCC-post  HCV  group  and 
the  HCV  positive  group.  Of  these  ten  deregulated 
miRNAs,  five  miRNAs  were  significantly 
down-regulated  (miR-323,  miR-449,  miR-520d, 
miR-516-5p and miR-650), while the other five miR-
NAs were up-regulated (miR-335, miR-618, miR-625, 
miR-532,  and  miR-7),  relative  to  the  control  group. 
The  common  deregulation  of  these  miRNAs  repre-
sented possible HCC biomarker candidates.  
It  was  decided  that  three  commonly 
down-regulated  miRNAs  (miR-323,  miR-449  and 
miR-520d) and two commonly up-regulated miRNAs 
(miR-335  and  miR-7)  would  not  be  investigated  as 
possible HCC biomarker candidates. The decision for 
not using miR-7 and miR-335 as biomarker candidates 
was based on their putative targets and a review of 
relevant literature. MiR-7 is thought to be an endo-
crine  miRNA,  highly  expressed  in  the  human  pan-
creatic islets (30). Since HCV is known to infect the 
pancreatic cells (31), the presence of miR-7 in both the 
HCC-post HCV positive group and the HCV positive 
group  may  have  resulted  from  the  destruction  of 
pancreatic  cells  as  part  of  the  cellular  immune  re-
sponse against HCV infection. As for miR-335, it re-
portedly inhibits tumor metastasis through regulating 
a set of genes whose expression is associated with a 
risk  of  distal  metastasis,  especially  in  breast  cancer 
(32). It is, therefore, not specific enough to be used as 
an HCC biomarker. 
Similarly to miR-7 and miR-335, three commonly 
down-regulated  miRNAs  (miR-323,  miR-449  and 
miR-520d) were excluded from this study based on 
specificity factors. The transforming growth factor-α 
(TGF-α)  is  thought  to  be  the  putative  target  of 
miR-323.  Growth  factors  are  generally  secreted  by 
tumor cells in an autocrine fashion and are considered 
important  factors  in  tumorigenesis  (33).  TGF-α  has 
been reported to be over-expressed in various tumor 
tissues, and is likely to be associated with the occur-
rence of lymph nodes, liver metastases and short sur-
vival (34). TGF-α is also over-expressed in colorectal 
carcinoma and is associated with poor prognosis of 
this cancer (35). It is likely that expression of miR-323 
down-regulates  the  expression  of  TGF-α;  conse-
quently, the down-regulation of miR-323 leads to the 
uncontrolled over-expression of TGF-α.  
As expected, up-regulation of the putative tar-
gets of miR-449 and miR-520d, Stathmin 1 and Matrin 
3, respectively, was previously reported in the Pro-
teomic-based  biomarker  approach.  As  a  reminder, 
Matrin  3  has  been  identified  by  the  HPLC-MS/MS 
analysis  in  proteins  pooled  from  the  HCV  positive 
group, whereas Stathmin 1 was commonly present in 
both the HCC-post HCV positive group and the HCV 
positive  group.  Stathmin  1  over-expression  in  HCC 
patients was associated with higher vascular invasion 
and considered to be an important prognostic factor 
for HCC, which may serve as a useful marker to pre-
dict early tumor recurrence (ETR) (36). Matrin 3 is an 
RNA-binding protein, reported to be one of the cel-
lular proteins that interacts with the 3' UTR of HCV 
and  that  plays  a  role  in  HCV  replication  and 
HCV-associated pathogenesis (37). Theoretically, the 
down-regulation of both miR-449 as well as miR-520d 
should  be  followed  by  the  over-expression  of  their 
putative targets (i.e. Stathmin 3 and Matrin 3) and this 
was confirmed by the data generated from the pro-
teomic-based approach.  
Thus,  we  focused  on  5  miRNAs  (miR-516-5p, 
miR-650, miR-625, miR-532 and miR-618) as possible 
HCC  biomarker  candidates  among  high-risk  HCV 
patients. Based on the TargetScan and MiRanda da-
tabases, miR-516-5p, miR-650, miR-625, miR-532 and 
miR-618 were found to possibly target genes related 
to HCC development and progression.  
We reviewed the putative targets of the chosen 
miRNAs closely in order to explain the significance of 
the deregulation of their expression in the context of 
HCC.  The  putative  target  of  miR-650  is  TRAF4. 
TRAF4 is likely to play an important role in carcino-
genesis as it was suggested that its over-expression 
could  participate  in  and/or  promote  tumorigenesis 
(38).  Accordingly,  we  hypothesized  that  its 
over-expression was a result of the down-regulation 
of its regulator, miR-650. MiR-650 is, therefore, a pos-
sible  tumor-suppressor  gene  and,  thus,  a  potential  Journal of Cancer 2012, 3 
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candidate HCC biomarker among the high-risk HCV 
positive population. 
The putative target of miR-516-5p is Glypican 3 
(GPC3). The serum level of GPC3 is significantly ele-
vated in patients with HCC in comparison to healthy 
individuals or patients with nonmalignant liver dis-
eases (39). It has already been suggested that GPC3 
could be used as a marker for HCC (40), therefore, the 
down-regulation of miR-516-5p, which is a theoretical 
regulator of GPC3 expression, could also be a poten-
tial  HCC  biomarker  among  high-risk  HCV  positive 
patients. 
The putative target of the up-regulated miR-625 
is methyl-CpG-binding domain 2 (MBD2). MBD2 is 
one of five known MBD containing proteins (41) that 
specifically bind to any methylated gene and mediate 
its  transcriptional  repression  (42).  Given  the  epige-
netic role of MBD proteins in regulating gene expres-
sion, they may also be  involved in cancer develop-
ment  by  affecting  the  expression  of  cancer-related 
genes (43). MBD2 has been reported to bind specifi-
cally to methylated gene promoters and recruit his-
tone deacetylases and chromatin remodeling proteins. 
Consequently, the binding of these factors leads to the 
alteration of the chromatin structure that may be re-
sistant to transcriptional machinery, causing repres-
sion of gene expression (44). In accordance with our 
data  which  showed  that  a  large  number  of  tu-
mor-suppressor  genes  were  methylated  (“silenced”) 
among  HCC-post  HCV  positive  patients,  the 
up-regulation  of  miRNA-625  may  serve  to  reduce 
aberrant methylation events of TSGs by targeting the 
MBD2 protein and, thus, decrease the tumor growth 
rate.  Therefore,  miR-625  may  have  a  tu-
mor-suppressor role. 
The putative target of miR-532 is the DNA ligase 
I (LIG 1), which plays an important role in DNA rep-
lication. It has been reported that DNA ligase I is re-
sponsible for the majority of DNA ligase activity in 
proliferating cells compared to non-dividing or rest-
ing  cells  (45,  46).  In  2001,  Sun  et  al.,  reported  the 
presence of high DNA ligase I activity in tumor tis-
sues compared to normal tissues. This activity may 
improve the survival of tumor cells, especially in the 
presence of anti-cancer drugs, which directly or indi-
rectly damage DNA. It was also postulated that DNA 
ligase I could be used as a unique target for the design 
of new anti-cancer agents (47). Therefore, we assumed 
that  the  up-regulation  of  miR-532  is  a  natural  an-
ti-cancer response that can target and suppress DNA 
ligase I over-expression and, thus, can be used as an 
HCC biomarker candidate.  
As for miR-618, it was found to possibly target 
the  Low-Density  Lipoprotein  Receptor-Related  Pro-
tein 12 (LPR12), which was firstly identified by Qing 
et al. in 1999. LPR 12 was found to be expressed in 
normal tissues and was decreased in corresponding 
malignant tissues (48). Several studies have demon-
strated that LPR 12 can act as a tumor suppressor gene 
as tumor formation/growth was not reduced when it 
was down-regulated (49). Since LPR 12 was found to 
be the putative target of miR-618, miR-618 is thought 
to  function  as  an  oncogene.  The  up-regulation  of 
miR-618 could suppress LPR 12 expression and lead 
to  the  progression  of  HCC.  Therefore,  the 
up-regulation of mir-618 was evaluated as a possible 
HCC biomarker. 
Based on the above-mentioned correlations be-
tween the observed deregulated miRNAs and HCC 
progression and development, we decided to evaluate 
the deregulations of expression of miR-625, miR-532, 
miR-618,  miR-516-5p  and  miR-650  as  non-invasive 
biomarkers  for  the  early  diagnosis  of  HCC  among 
high-risk HCV positive patients. Initially, we found 
that  miR-625,  miR-532  and  miR-618  were 
up-regulated  in  56%,  62.5%  and  72%  of  HCC-post 
HCV  positive  patients,  respectively.  In  addition, 
miR-516-5P  and  miR-650  were  found  to  be 
down-regulated in 50% and 72% of HCC-post HCV 
positive  patients,  respectively.  Interestingly,  the 
down-regulation  of  miR-516-5p  among  50%  of  the 
HCC-post HCV-positive patients agrees with the di-
agnostic value of its putative target, Glypican3, which 
can correctly identify HCC with a sensitivity of 50% 
(40). Importantly, these results suggested that the de-
regulation of both miR-618 and miR-650 is a charac-
teristic miRNA signature of HCC among HCV posi-
tive patients (72%). This is in accordance with their 
putative roles as regulators of genes involved in HCC 
progression and development. MiR-618 up-regulation 
suppresses  the  expression  of  the  tumor-suppressor 
gene (LPR12) and miR-650 down-regulation leads to 
the over-expression of TARF4.  
To  evaluate  the  potential  of  using  miR-618 
and/or miR-650 as urinary miRNA-based biomarkers 
for the early detection of HCC among high-risk HCV 
positive patients, we studied their expression among 
HCV  positive  patients  who  were  not  diagnosed  as 
HCC patients at the time of initial sample collection. 
The expression levels of miR-618 and miR-650 among 
HCV positive patients, relative to the control group, 
were evaluated using RT-qPCR. MiR-618 was signif-
icantly (≥ 3 fold difference of expression and p value < 
0.05) up-regulated in 35 of the 74 HCV positive pa-
tients,  whereas  miR-650  was  significantly 
down-regulated in 42 of the 74 HCV positive patients. 
The  patients  who  were  exhibiting  either  significant 
up-regulation  of  miR-618  or  significant  Journal of Cancer 2012, 3 
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down-regulation of miR-650 were suspected as HCC 
patients. In order to evaluate the diagnostic value of 
the deregulation of these two miRNAs for identifying 
HCC among chronic HCV positive patients, the med-
ical records of the HCV infected patients, specifically 
their AFP levels and CT scan results, were updated 
two years after initial sample collection. The updated 
records showed that AFP levels were elevated in 35 
HCV infected patients, all of whom also tested posi-
tive for HCC by CT scans. Only one patient, #7, had a 
normal AFP level, but was diagnosed with HCC by 
CT scan. In total, 36 patients were identified as having 
developed cancer. 
Of  the  35  HCV  positive  patients  who  showed 
significant  up-regulation  of  miR-618,  23  were  con-
firmed as HCC positive based on the updated medical 
records. Furthermore, 26 of the 42 HCV patients who 
showed significant down-regulation of miR-650 were 
confirmed as HCC positive. The sensitivity and speci-
ficity of miR-618 for detecting HCC among HCV pos-
itive patients were 64% and 68%, respectively, with an 
overall diagnostic accuracy of 66%. The Positive pre-
dictive value (PPV) of miR-618 for correctly identify-
ing  true  HCC  positive  patients  was  66%  and  the 
Negative predicative value (NPV) for correctly iden-
tifying true negative HCC patients was 67%. Whereas, 
the sensitivity and specificity of miR-650 for detecting 
HCC  among  HCV-positive  patients  were  72%  and 
58%, respectively, with an overall diagnostic accuracy 
of 65%. The PPV of miR-650 for correctly identifying 
true HCC positive patients was 62% and the NPV for 
correctly identifying true negative HCC patients was 
69%. Additionally, the sensitivity and specificity for 
miR-618/  miR-650  tandem  were  58%  and  75%,  re-
spectively, with an overall diagnostic accuracy of 69%. 
The PPV of miR-618/miR-650 for correctly identifying 
true HCC positive patients was 68% and the NPV for 
correctly identifying true negative HCC patients was 
70%.  
Despite the poor predictive values of our find-
ings, the sensitivity of miR-650 and the specificity of 
the  mir-618/miR-650  combination  were  greatly  im-
proved  compared  to  the  AFP  level-based  detection 
method  (sensitivity  of  68%  and  specificity  of  75%) 
(50).The proposed HCC miRNA signatures may be of 
great value for the early diagnosis of HCC, before the 
onset of the disease, among high-risk HCV infected 
patients. The significance of this approach is ampli-
fied by the sample source (urine) from which these 
miRNA signatures were extracted. The advantage of 
using urine as a sample source for studying diseases is 
that it offers a non-invasive approach for developing 
screening tools that can reduce worldwide mortality 
rates.  
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